Metuchen Pharmaceuticals goal is to take men’s health to new heights through passion, vision and partnerships

WASHINGTON, DC, September 2016 – Juggernaut Capital Partners (“Juggernaut”), a leading private equity firm focusing on lower middle market companies primarily in the consumer and business services sectors, is pleased to announce it has made an investment in Metuchen Pharmaceuticals, a Freehold, New Jersey-based men’s health-focused company.

Metuchen’s mission is to be an innovator of clinical health solutions, and a driver of change in the overall men’s health landscape. The company is dedicated to raising awareness about men’s health issues and driving improvements for those affected.

Metuchen’s portfolio of men’s health products includes the PDE-5 inhibitor drug Stendra® which is an FDA and EMEA approved PDE-5 inhibitor drug used to treat erectile dysfunction. Stendra was initially launched in late 2013 and is patent protected through 2025.

About Metuchen Pharmaceuticals

Metuchen Pharmaceuticals is a men’s health-focused specialty pharmaceutical company. Metuchen was formed to acquire the rights to license, develop, market, sell and distribute STENDRA® (avanafil), an FDA-approved PDE5 inhibitor drug used to treat erectile dysfunction.  The company is headquartered in Freehold, New Jersey.

About Juggernaut Capital Partners

Juggernaut Capital Partners is a leading private equity firm focusing on lower middle market companies primarily in the consumer and business services sectors. Juggernaut has a family of funds representing over $600 million of capital commitments and is currently investing out of Juggernaut Capital Partners III, L.P.

For more information on Juggernaut Capital Partners, please visit www.juggernautcap.com.